| Previous Close | 37.63 |
| Open | 37.66 |
| Bid | 37.31 x 100 |
| Ask | 55.00 x 300 |
| Day's Range | 37.30 - 37.89 |
| 52 Week Range | 20.68 - 40.83 |
| Volume | 867,543 |
| Avg. Volume | 1,395,350 |
| Market Cap | 4.6B |
| Beta | 4.45 |
| PE Ratio (TTM) | -14.84 |
| EPS (TTM) | -2.53 |
| Earnings Date | Nov 6, 2017 - Nov 10, 2017 |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 44.89 |
Markit•yesterdaySee what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc NASDAQ/NGS:ACAD
- Motley Fool•2 days ago
Billionaires Are Gobbling Up This Beaten-Down Biotech Stock: Should You?
Billionaire superinvestors Felix and Julian Baker started buying shares of the beaten-down vaccine maker Novavax in the second quarter.
- Zacks•4 days ago
Supernus Drops SPN-810's Lower Dose Test in Phase III Trials
Supernus (SUPN) decides to stop evaluating the lower dose option of SPN-810 for treatment of impulsive aggression. However, the company will carry on with the study of higher dose arm or placebo.
